

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT: NOVEMBER 5, 2003

NEOPROBE CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Delaware	0-26520	31-1080091
-----	-----	-----
(STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)	(COMMISSION FILE NO.)	(IRS EMPLOYER IDENTIFICATION NUMBER)

425 Metro Place North, Suite 300
Columbus, Ohio 43017
(614) 793-7500
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER
INCLUDING AREA CODE OF REGISTRANT'S
PRINCIPAL EXECUTIVE OFFICES)

Not Applicable
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) EXHIBITS.

Exhibit No.	Description
99	Neoprobe Corporation press release dated November 5, 2003.

ITEM 9. REGULATION FD DISCLOSURE.

On November 5, 2003, Neoprobe Corporation (the "Company") issued a press release regarding the interview of David C. Bupp, the Company's President and Chief Executive Officer by Wall Street Reporter, an online business news service. A copy of the Company's press release is furnished as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99 furnished herewith, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liability of that Section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify

forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOPROBE CORPORATION

Date: November 5, 2003 By: /s/Brent L. Larson

Brent L. Larson
Vice President, Finance and Chief
Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99	Neoprobe Corporation press release dated November 5, 2003.

IMMEDIATE RELEASE NOVEMBER 5, 2003
CONTACTS:
BRENT L. LARSON, JONATHAN FASSBERG,
VP FINANCE & CFO THE TROUT GROUP
614 793 7500 212 437 9007

NEOPROBE'S CEO INTERVIEWED BY WALLSTREETREPORTER.COM

DUBLIN, OHIO - November 5, 2003 -- Neoprobe Corporation (OTCBB: NEOP), today announced that its President and Chief Executive Officer, David C. Bupp, was interviewed by Wall Street Reporter, an online business news service.

In the interview, Mr. Bupp briefly discussed Neoprobe's current development activities including those relating to the Company's line of gamma detection devices, its line of Quantix™ blood flow measurement devices, and its lymphatic mapping radiotracer Lymphoseek™. Among the highlights covered by Mr. Bupp were recent clinical presentations on the Quantix/ND™ and Quantix/OR™ products and a discussion of Lymphoseek's longer term revenue potential of approximately \$30 - - 40 million annually. Mr. Bupp concludes the interview with a brief investment overview for the Company.

To listen to Mr. Bupp's interview, go to www.wallstreetreporter.com. First-time users to Wall Street Reporter will have to register to listen to the interview. Scroll down to in the interviews dialog box to Neoprobe Corporation, David Bupp, and then click on the title.

ABOUT NEOPROBE

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe's current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the acquisition of Cardiosonix Ltd. in 2001, Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is a development stage company that has recently received regulatory clearance to begin the clinical evaluation and commercial sale of its blood flow measurement products. Cardiosonix' products (the Quantix/ND™ and the Quantix/ORTM) are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians.

Statements in this news release and the interview, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and exclusive distributor, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.